SEC Tracker
Get the app

Novint Technologies DROR

Novint Technologies FY 2021: revenue $3K, up 157%; diluted EPS $0.00

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Novint Technologies reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$3K+157% from $1K in FY 202010-K income statement, on EDGAR
  2. Net income−$171KAgainst −$168K in FY 202010-K income statement, on EDGAR
  3. Diluted EPS$0.00Against $0.00 in FY 202010-K income statement, on EDGAR
  4. Cash and cash equivalents$186K−42% from $322K in FY 202010-K balance sheet, on EDGAR
  5. Cash from operations−$136KAgainst −$110K in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Novint Technologies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3843 and related industry codes: the same peer list as the financial tables.

  1. Neuraxis NRXS public float $20M, Jun 30, 2025
  2. Allurion Technologies ALUR public float $21M, Jun 30, 2025
  3. Positron POSC public float $22M, Jun 30, 2025
  4. Vivos Therapeutics VVOS public float $23M, Jun 30, 2025
  5. Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025